Probiotics in pediatric inflammatory bowel diseases

Current Gastroenterology Reports

Volumn 11, Issue 3, 2009, Pages 238-247

  Gulati, Ajay S ^a   Dubinsky, Marla C ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ANTIDIARRHEAL AGENT; AZATHIOPRINE; BALSALAZIDE; BIFIDOBACTERIUM LONGUM EXTRACT; CIPROFLOXACIN; CORTICOSTEROID; ESCHERICHIA COLI NISSLE 1917; FLORA Q; GENTAMICIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INULIN; LACTOBACILLUS RHAMNOSUS GG; MESALAZINE; METRONIDAZOLE; ORNIDAZOLE; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; SACCHAROMYCES BOULARDII EXTRACT; SALAZOSULFAPYRIDINE; STEROID; SYNBIOTIC 2000; SYNBIOTIC AGENT; UNCLASSIFIED DRUG; VSL3;

ALTERNATIVE MEDICINE; BIFIDOBACTERIUM; BIFIDOBACTERIUM LONGUM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CROHN DISEASE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; ENTERITIS; ESCHERICHIA COLI; HUMAN; ILEITIS; LACTOBACILLUS RHAMNOSUS; LOW DRUG DOSE; MAINTENANCE THERAPY; OUTCOME ASSESSMENT; POSTOPERATIVE CARE; REMISSION; REVIEW; SACCHAROMYCES BOULARDII; T CELL LYMPHOMA; ULCERATIVE COLITIS;

CHILD; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINES; PROBIOTICS; TREATMENT OUTCOME;

EID: 66149156573     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-009-0037-z     Document Type: Review

References (49)

1. Sartor RB: MechanPsms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006, 3:390-407.
2. Sartor RB: Microbial influences in inflammatorR bowel disease: role in pathogenesis and clinical implications. In Kirsner's Inflammatory Bowel Diseases, edn 6. Edited by Sartor RB, Sandborn WJ. Philadelphia: Elsevier; 2004:138-162.
3. D'Haens GR, Geboes K, Peeters M, et al.: Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998, 114:262-267.
4. Joint Food and Agriculture Organization of the United Nations/World Health Organization Working Group: Guidelines for the evaluation of probiotics in food. Available at http://www.who.int/foodsafety/ fs_management/en/probiotic_guidelines.pdf. Accessed April 2009.
5. Bohm SD, Kruis W: Probiotics: do they help to control intestinal inflammation? Ann N Y Acad Sci 2006, 1072:339-350.
6. Van Niel CW, Feudtner C, Garrison MM, Christakis DA: Lactobacillus therapy for acute infectious diarrhea in children: A meta-analysis. Pediatrics 2002, 109:678-684.
7. Szajewska H, Skorka A, Ruszczynski M, Gieruszczak-Bialek D: Meta-analysis: Lactobacillus GG for treating acute diarrhoea in children. Aliment Pharmacol Ther 2007, 25:871-881.
8. Lin HC, Hsu CH, Chen HL, et al.: Oral probiotics prevent necrotizing enterocolitis in very low birth weight preterm infants: A multicenter, randomized, controlled trial. Pediatrics 2008, 122:693-700.
9. Rosh JR, Gross T, Mamula P, et al.: Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: A cautionary tale? Inflamm Bowel Dis 2007, 13:1024-1030.
10. Gerasimidis K, McGrogan P, Hassan K, Edwards CA: Dietary modifications, nutritional supplements and alternative medicine in paediatric patients with inflammatory bowel disease. Aliment Pharmacol Ther 2008, 27:155-165.
11. Kong SC, Hurlstone DP, Pocock CY, et al.: The incidence of self-prescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J Clin Gastroenterol 2005, 39:138-141.
12. Rembacken BJ, Snelling AM, Hawkey PM, et al.: Nonpathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: A randomised trial. Lancet 1999, 354:635-639.
13. Kato K, Mizuno S, Umesaki Y, et al.: Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 2004, 20:1133-1141.
14. Furrie E, Macfarlane S, Kennedy A, et al.: Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: A randomised controlled pilot trial. Gut 2005, 54:242-249.
15. Tursi A, Brandimarte G, Giorgetti GM, et al.: Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 2004, 10:I126-I131.
16. Bibiloni R, Fedorak RN, Tannock GW, et al.: VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005, 100:1539-1546.
17. Huynh HQ, Debruyn J, Guan L, et al.: Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: A pilot study. Inflamm Bowel Dis 2008 (Epub ahead of print).
18. Guslandi M, Giollo P, Testoni PA: A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 2003, 15:697-698.
19. Tsuda Y, Yoshimatsu Y, Aoki H, et al.: Clinical effectiveness of probiotics therapy (BIO-THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand J Gastroenterol 2007, 42:1306-1311.
20. Kruis W, Schutz E, Fric P, et al.: Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997, 11:853-858.
21. Kruis W, Fric P, Pokrotnieks J, et al.: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004, 53:1617-1623.
22. Henker J, Muller S, Laass MW, et al.: Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: An open-label pilot study. Z Gastroenterol 2008, 46:874-875.
23. Zocco MA, dal Verme LZ, Cremonini F, et al.: Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 2006, 23:1567-1574.
24. Malchow HA: Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997, 25:653-658.
25. Schultz M, Timmer A, Herfarth HH, et al.: Lactobacillus GG in inducing and maintaining remission of Crohn's disease. BMC Gastroenterol 2004, 4:5.
26. Gupta P, Andrew H, Kirschner BS, Guandalini S: Is lactobacillus GG helpful in children with Crohn's disease? Results of a preliminary, open-label study. J Pediatr Gastroenterol Nutr 2000, 31:453-457.
27. Fujimori S, Tatsuguchi A, Gudis K, et al.: High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J Gastroenterol Hepatol 2007, 22:1199-1204.
28. Doman DB, Goldberg HJ, Golding MI: "Ecologic niche" therapy for Crohn's disease with adjunctive rifaximin antibiotic treatment followed by Flora-Q probiotic maintenance therapy. Am J Gastroenterol 2008, 103:251-252.
29. Guslandi M, Mezzi G, Sorghi M, Testoni PA: Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000, 45:1462-1464.
30. Akobeng AKT Review article: the evidence base for interventions used to maintain remission in Crohn's disease. Aliment Pharmacol Ther 2008, 27:11-18.
31. Bousvaros A, Guandalini S, Baldassano RN, et al.: A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm Bowel Dis 2005, 11:833-839.
32. Rutgeerts P, Hiele M, Geboes K, et al.: Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995, 108:1617-1621.
33. Rutgeerts P, Van AG, Vermeire S, et al.: Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: A randomized, double-blind, placebo-controlled trial. Gastroenterology 2005, 128:856-861.
34. Prantera C, Scribano ML, Falasco G, et al.: Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: A randomised controlled trial with Lactobacillus GG. Gut 2002, 51:405-409.
35. Marteau P, Lemann M, Seksik P, et al.: Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: A randomised, double blind, placebo controlled GETAID trial. Gut 2006, 55:842-847.
36. Van Gossum A, Dewit O, Louis E, et al.: Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection. Inflamm Bowel Dis 2007, 13:135-142.
37. Chermesh I, Tamir A, Reshef R, et al.: Failure of Synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Dig Dis Sci 2007, 52:385-389.
38. Hahnloser D, Pemberton JH, Wolff BG, et al.: Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Br J Surg 2007, 94:333-340.
39. Sartor RB: Probiotics in chRonic pouchitis: restoring luminal microbial balance. Gastroenterology 2000, 119:584-587.
40. Kuisma J, Mentula S, Jarvinen H, et al.: Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003, 17:509-515.
41. Gionchetti P, Rizzello F, Morselli C, et al.: High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 2007, 50:2075-2082.
42. Gionchetti P, Rizzello F, Venturi A, et al.: Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: A double-blind, placebo-controlled trial. Gastroenterology 2000, 119:305-309.
43. Mimura T, Rizzello F, Helwig U, et al.: Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004, 53:108-114.
44. Shen B, Brzezinski A, Fazio VW, et al.: Maintenance therapy with a probiotic in antibiotic-dependent pouchitis: Experience in clinical practice. Aliment Pharmacol Ther 2005, 22:721-728.
45. Gionchetti P, Rizzello F, Helwig U, et al.: Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology 2003, 124:1202-1209.
46. Gosselink MP, Schouten WR, van Lieshout LM, et al.: Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum 2004, 47:876-884.
47. Venturi A, Gionchetti P, Rizzello F, et al.: Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999, 13:1103-1108.
48. Ishikawa H, Akedo I, Umesaki Y, et al.: Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 2003, 22:56-63.
49. Laake KO, Bjorneklett A, Aamodt G, et al.: Outcome of four weeks' intervention with probiotics on symptoms and endoscopic appearance after surgical reconstruction with a J-configurated ileal-pouch-anal-anastomosis in ulcerative colitis. Scand J Gastroenterol 2005, 40:43-51.